


Supplementary Materials: Breast-Associated Adipocytes Secretome Induce Fatty Acid Uptake and Invasiveness in Breast Cancer Cells via CD36 Independently of Body Mass Index, Menopausal Status and Mammary Density

Maurice Zaoui, Mehdi Morel, Nathalie Ferrand, Soraya Fellahi, Jean-Philippe Bastard, Antonin Lamazière, Annette Kragh Larsen, Véronique Béréziat, Michael Atlan and Michèle Sabbah



	Non Ob		Ob		Low D		High C		Pre M		Post M	
	D0	D14	D0	D14	D0	D14	D0	D14	D0	D14	D0	D14
PPAR γ	0.02357644	0.55473104	0.00570736	0.51658066	0.00999297	0.54375981	0.0170117	0.5330375	0.00895798	0.52812307	0.02763506	0.55649261
FABP4	0.00944453	1.82557544	0.01444163	1.94452062	0.01174121	1.92930307	0.010490924	1.78892917	0.01450824	1.92877003	0.00684606	1.78972872
Tubulin	3847340.96	4079989.33	3115301.67	4831050	3718620.44	4617883.33	3860917.568	4024209	3009060.16	4556796	4372722.87	4115840

Figure S1. The whole blot showing all the bands with all molecular weight markers on the western blotting.




Figure S2. Fatty acids profiles of ASCs-conditioned medium.




Figure S3. Bar chart representing the proliferation of cells treated with control or ASCs-conditioned medium at 12, 24, 48 and 72 h. n.s. no significance; $p \geq 0.05$; ** $p < 0.01$; **** $p < 0.0001$.




Figure S4. Western blot quantification. n.s. $p \geq 0.05$; * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.




Figure S5. The whole blot showing all the bands with all molecular weight markers on the western blotting.




Figure S6. The whole blot showing all the bands with all molecular weight markers and western blot quantification.




Figure S7. CD36 inhibition reduces adipocyte-induced fatty acid uptake.

Table S1. Characteristics of the women.

Patient	Age	Height (m)	Weight (kg)	BMI (kg/m ²)	Mammary Density	Menopausal Status
Patient 1	35	1.62	88	33.5	Low D	–
Patient 2	43	1.6	71	27.7	Low D	–
Patient 3	54	1.55	53	22.1	Low D	+
Patient 4	61	1.58	65	26	High D	+
Patient 5	56	1.6	76	30	Low D	+
Patient 6	62	1.63	70	26.3	Low D	+
Patient 7	16	1.63	63	23.7	High D	–
Patient 8	50	1.72	78	26.4	High D	+
Patient 9	18	1.75	105	34.3	Low D	–
Patient 10	60	1.62	91	34.7	Low D	+
Patient 11	51	1.65	72	26.4	High D	+
Patient 12	51	1.72	78	26.4	Low D	+
Patient 13	55	1.63	80	30.1	High D	+
Patient 14	17	1.7	80	27.7	High D	–
Patient 15	18	1.68	83	30	Low D	–
Patient 16	44	1.77	71	22.7	High D	–

Table S2. list of primers.

Gene	Forward	Reverse
D36	TGGTACAGATGCAGCCTCAT	AGGCCTTGGATGGAAGAACA
FABP4	GGGCCAGGAATTTGACGAAG	ACTTCAGTCCAGGTCAACGT
FABP5	GCTGAACCAATGCACCATCT	AGGAGTGGGAATAGCTTTGCG
PPAR γ	TTGCAGTGGGGATGTCTCAT	TTTCCTGTCAAGATCGCCCT
SLC27A2	ACCACAGGTCTTCCAAAAGCA	AGTCCGCAAGGCAAGAGTAG
VLDLR	GAATGTGAGGATGGCAGCTG	CAGTCCTGCTCCTGGTTACA
β Actine	GGACTTCG AGCAAGAGATGG	AGCACTGTGTTGGCGTACAG
36B4	GGACTTCG AGCAAGAGATGG	AGCACTGTGTTGGCGTACAG



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).